Kalaris Therapeutics (KLRS) Institutional Ownership $2.27 -0.01 (-0.44%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Kalaris Therapeutics (NASDAQ:KLRS)CurrentInstitutional OwnershipPercentage66.05%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$64.70KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.08M Get KLRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Kalaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Kalaris Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025Gilead Sciences Inc.317,789$848K0.1%-56.1%1.699% 8/12/2025 XTX Topco Ltd24,234$65K0.0%N/A0.130% (Data available from 1/1/2016 forward) KLRS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KLRS shares? During the previous two years, the following institutional investors and hedge funds held shares of Kalaris Therapeutics shares: Gilead Sciences Inc. ($848K), XTX Topco Ltd ($65K).Learn more on Kalaris Therapeutics' institutional investors. What percentage of Kalaris Therapeutics' stock is owned by institutional investors? 66.05% of Kalaris Therapeutics' stock is owned by institutional investors. Learn more on KLRS's institutional investor holdings. Which institutional investors have been buying Kalaris Therapeutics' stock? The following institutional investors have purchased Kalaris Therapeutics' stock in the last 24 months: XTX Topco Ltd ($24.23K). How much institutional buying is happening at Kalaris Therapeutics? Institutional investors have bought a total of 24,234 shares in the last 24 months. This purchase volume represents approximately $64.70K in transactions. Which of Kalaris Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Kalaris Therapeutics stock in the last 24 months: Gilead Sciences Inc. ($405.48K). How much institutional selling is happening at Kalaris Therapeutics? Institutional investors have sold a total of 405,484 shares in the last 24 months. This volume of shares sold represents approximately $1.08M in transactions. Related Companies TRDA Institutional Ownership OGI Institutional Ownership IPHA Institutional Ownership GNFT Institutional Ownership CTMX Institutional Ownership EPRX Institutional Ownership ENGN Institutional Ownership EDIT Institutional Ownership TIL Institutional Ownership PBYI Institutional Ownership This page (NASDAQ:KLRS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access